Imexpharm Valuation

Is IMP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IMP (₫71000) is trading below our estimate of fair value (₫75652.23)

Significantly Below Fair Value: IMP is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMP?

Other financial metrics that can be useful for relative valuation.

IMP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.4x
Enterprise Value/EBITDA10.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does IMP's PE Ratio compare to its peers?

The above table shows the PE ratio for IMP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.3x
DBD Binh Dinh Pharmaceutical and Medical Equipment
17.1xn/a₫4.0t
TRA Traphaco
15.2xn/a₫3.5t
DCL Cuu Long Pharmaceutical
30.8xn/a₫1.9t
DMC Domesco Medical Import - Export
14.3xn/a₫2.2t
IMP Imexpharm
19.5xn/a₫5.0t

Price-To-Earnings vs Peers: IMP is expensive based on its Price-To-Earnings Ratio (19.5x) compared to the peer average (19.3x).


Price to Earnings Ratio vs Industry

How does IMP's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: IMP is good value based on its Price-To-Earnings Ratio (19.5x) compared to the Asian Pharmaceuticals industry average (24.9x).


Price to Earnings Ratio vs Fair Ratio

What is IMP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IMP's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₫71,000.00
₫77,033.33
+8.5%
3.9%₫81,100.00₫74,000.00n/a3
Apr ’25₫67,500.00
₫77,033.33
+14.1%
3.9%₫81,100.00₫74,000.00n/a3
Mar ’25₫66,800.00
₫77,033.33
+15.3%
3.9%₫81,100.00₫74,000.00n/a3
Feb ’25₫62,000.00
₫75,000.00
+21.0%
1.3%₫76,000.00₫74,000.00n/a2
Jan ’25₫56,600.00
₫79,047.62
+39.7%
1.2%₫80,000.00₫78,095.24n/a2
Dec ’24₫54,800.00
₫79,047.62
+44.2%
1.2%₫80,000.00₫78,095.24n/a2
Nov ’24₫57,000.00
₫79,047.62
+38.7%
1.2%₫80,000.00₫78,095.24n/a2
Oct ’24₫64,761.90
₫79,047.62
+22.1%
1.2%₫80,000.00₫78,095.24n/a2
Sep ’24₫65,523.81
₫79,047.62
+20.6%
1.2%₫80,000.00₫78,095.24n/a2
Mar ’24₫47,619.05
₫63,428.57
+33.2%
5.4%₫66,857.14₫60,000.00₫66,800.002
Feb ’24₫54,761.90
₫63,428.57
+15.8%
5.4%₫66,857.14₫60,000.00₫62,000.002
Jan ’24₫57,333.33
₫63,428.57
+10.6%
5.4%₫66,857.14₫60,000.00₫56,600.002
Dec ’23₫57,142.86
₫71,047.62
+24.3%
5.9%₫75,238.10₫66,857.14₫54,800.002
Nov ’23₫50,476.19
₫71,047.62
+40.8%
5.9%₫75,238.10₫66,857.14₫57,000.002
Oct ’23₫59,047.62
₫71,047.62
+20.3%
5.9%₫75,238.10₫66,857.14₫64,761.902
Sep ’23₫59,904.76
₫71,047.62
+18.6%
5.9%₫75,238.10₫66,857.14₫65,523.812
Jul ’23₫56,571.43
₫72,047.62
+27.4%
4.4%₫75,238.10₫68,857.14₫58,095.242
Jun ’23₫63,047.62
₫72,047.62
+14.3%
4.4%₫75,238.10₫68,857.14₫52,666.672
May ’23₫70,380.95
₫72,047.62
+2.4%
4.4%₫75,238.10₫68,857.14₫49,428.572
Apr ’23₫71,523.81
₫72,047.62
+0.7%
4.4%₫75,238.10₫68,857.14₫44,809.522

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.